Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions

ANCA-IgG-positive ANCA Associated Vasculitis

Interventions

DRUG

KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.